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Short-Term Prognosis of Juvenile
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Viscosity
Gregorio Caimi, MD1, Lo Presti R, MD1, Andolina G, MD1,
and Hopps E, MD1
In our early research1 regarding the hemorheological pattern in
patients with acute myocardial infarction (AMI) with a mean
age of 61.45+ 10.99 years, we showed that the major hemor-
heological parameters were almost normalized 2 weeks after
the acute event. In the last decade, we focused on hemorheo-
logical parameters in juvenile myocardial infarction (JMI),
defined as AMI in patients aged 45 years, in the ‘‘Sicilian
study on juvenile myocardial infarction’’.2,3
Juvenile myocardial infarction is responsible for 2% to 10%
of all cases with AMI in different surveys.4,5 Juvenile myocar-
dial infarction presents a typical pattern of risk factors6,7 and
shows clinical, angiographic, and prognostic characteristics.5
Regarding risk factors, cigarette smoking is by far the most
common, followed by family history of coronary artery disease
and hypercholesterolemia, while arterial hypertension and dia-
betes mellitus are less frequent. Juvenile myocardial infarction
may be associated with the use of oral contraceptives, preg-
nancy, or cocaine abuse as well as with congenital coronary
artery abnormalities. Concerning the clinical picture, patients
with JMI reach hospital earlier than older patients, enhancing
the effectiveness of revascularization procedures and treatment
of complications. In JMI, the absence of coronary stenosis is
often demonstrated or just 1 coronary vessel is affected; 2- or 3-
vessel disease is infrequent. Generally, patients with JMI have
a lower incidence of complications, such as early and late heart
failure, angina, reinfarction, and atrioventricular block; mortal-
ity during hospitalization and after 6 months is significantly
reduced.
In the Sicilian study, we observed a pattern of inflammatory
polymorphisms in patients with JMI.8 A higher prevalence of
proinflammatory polymorphisms (SNP A2080G of pyrin gene,
SNP Gly670Arg of PECAM gene, C1019T of Cx 37 gene, and
SNP G1059C of PCR gene) and a lower prevalence of anti-
inflammatory polymorphisms (Asp299Gly of TLR4 gene, SNP
– 1082 G/A of IL10 gene, CCR5D32) were present.
We revisited plasma viscosity (PV) in our survey of patients
with JMI and considered 2 aspects in particular. The first is the
potential role played by PV in the dynamics of myocardial
microcirculation (namely, in the phenomenon of coronary slow
flow) that may be secondary to AMI9-11; the second aspect was
life expectancy.
Plasma viscosity is dependent on the plasma protein con-
centration, although the contribution of different proteins
(fibrinogen, a2-macroglobulin, immunoglobulins, haptoglobin,
and ceruloplasmin) differs in relation to their molecular size
and shape; the plasma protein composition can also change due
to pathophysiological processes.12 The PV plays a pivotal role,
together with erythrocyte deformability and platelets, in micro-
circulatory blood flow.13
In this editorial, we describe the behavior of PV in 120
patients with JMI (109 men; mean age 39.4+ 5.8 years); the
time interval between AMI onset and the first hemorheological
evaluation was 13 + 7 days. Using fasting venous blood, we
measured PV at the shear rate of 450 s1 using the cone-and-
plate viscometer Wells-Brookfield mod ½ LVT (Middleboro,
Massachusetts). We reexamined this parameter 3 (n ¼ 83) and
12 (n ¼ 70) months after AMI.
At the initial stage, PV was increased compared to controls
(CS 1.259+ 0.125 vs JMI 1.519 + 0.108 mPa- s, P < .001).
The PV did not differ between ST-segment elevation myocar-
dial infarction (STEMI) and non-STEMI as well as in 3 sub-
groups of the patients with JMI subdivided according to the
number of cardiovascular risk factors (39 had 0 or 1 risk factor,
39 had 2 risk factors, and 42 had  3). Coronary angiography
was performed in 103 patients; no significant coronary stenosis
was demonstrated in 23, 46 had a single vessel disease, and 34
had multi-vessel disease. The PV did not differ between the 3
subgroups. At 3 and 12 months after AMI, PV was persistently
increased compared to controls (at 3 months 1.466 + 0.119
mPa- s and at 12 months 1.475+ 0.009 mPa-s, respectively).
Although the literature has described a low incidence of
cardiovascular complications in JMI,5 in our survey, follow-
up carried out for as long as 18 months showed that 5 patients
developed heart failure, 15 a new ischemic event (angina in 12
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and reinfarction in 3), and 4 had an ischemic event associated
with heart failure. The drugs prescribed at hospital discharge
were in agreement with current recommendations (antiplatelet
agent in 96.69%, statin in 75.31%, and a beta-blocker in
64.45%); however, enrollment started in 2001 and at that time
the use of 2 antiplatelet agents after AMI was not common.
Considering the number of patients who developed cardio-
vascular complications, we reexamined PV measured at the
initial stage, in patients with JMI with (n ¼ 24) and without
(n ¼ 74) cardiovascular events (CEs). The PV was initially
higher in the subgroup that subsequently developed CE (JMI
without CE 1.500 + 0.107 vs JMI with CE 1.555 + 0.094
mPa-s, P < .05).
Considering that several studies investigated the neutrophil
to lymphocyte ratio (NLR) in patients with AMI not selected
for age,14,15 we subdivided our patients with JMI into 2 sub-
groups according to the median NLR value. In the subgroup
with high NLR, PV was higher (JMI þ low NLR 1.492 +
0.097 vs JMI þ high NLR 1.545 + 0.113 mPa-s, P < .01,
respectively).
While the subdivision of patients with JMI according to the
NLR supports the role of PV as part of the acute-phase reac-
tion,16 its behavior in the patients subdivided according to
short-term cardiovascular outcomes suggests an influence on
coronary microcirculation. The regulation of myocardial
microcirculation has been extensively analyzed,17 and blood
viscosity was shown to be linked to the hemodynamic profile
in small and large vessels.18 The association of a significantly
increased PV with small-vessel occlusion was also described in
ischemic cerebral disease.19
Some studies showed a link between PV and the risk of
cardiovascular diseases20,21 as well as a relationship between
PV and the severity of coronary artery disease.22,23 It has been
recently observed that PV was positively associated with the
incidence of cardiovascular and noncardiovascular death dur-
ing the long-term follow-up of a male population.24 Similar to
what was described in patient with unstable angina,25 trans-
mural myocardial infarction,26 and in no-reperfusion STEMI
who had undergone primary coronary intervention,27 PV also
seemed to have a prognostic value in our survey. Therefore, the
persistence of a hemorheological alteration can be detrimental
to coronary hemodynamics, contributing to the phenomenon of
secondary coronary slow flow.9-11 Since the increase of PV in
patients with JMI persisted after 12 months, monitoring the
hemorheological profile and its possible response to drugs
should be given further attention.
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